Close
Nordic 9Nordic 9

Phase2Phase Biopharma (investor - Others)

Sweden
See something wrong or missing? Let us know
Offices:Stockholm

Phase2Phase Biopharma is a privately held Swedish company founded in 2017 by Svante Almkvist and Andreas Gretander.

Average round investment:679k USD
Average number per year:1.0
Distribution: 2025 (1)2024 (1)
Portfolio companies: Sweden VakonaSweden AAX Biotech
Mostly invests in: Sweden Sweden (2) Health services (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Phase2Phase Biopharma

Name Criteria
Sweden Vätterledens Invest AB
73%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Mattias Ankerberg
73%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden JFB Invest
73%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Hjalmar Didrikson
73%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden LIU Invest (Linköping University)
72%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 2.9
  • Active last 12 months: Yes
Sweden FundedByMe
72%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 3.6
  • Active last 12 months: Yes
Sweden Vasa Angels
72%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Sweden Simon Josefsson
72%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 3.9
  • Active last 12 months: Yes
Sweden Hans Victor
72%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Germany ProVeg Incubator
71%
  • Range for average deal size: 0.5M - 1M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Top